RhumbLine Advisers’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

RhumbLine Advisers’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-17,002	Closed	-$58K	–	3175
2021 Q1	$58K	Buy	17,002 +664	+4%	+$12.5K	﹤0.01%	2971
2020 Q4	$314K	Buy	16,338 +1,892	+13%	+$29.2K	﹤0.01%	2643
2020 Q3	$194K	Sell	14,446 -1,538	-10%	-$43.6K	﹤0.01%	2700
2020 Q2	$677K	Buy	15,984 +3,975	+33%	+$129K	﹤0.01%	2210
2020 Q1	$332K	Sell	12,009 -400	-3%	-$11.7K	﹤0.01%	2351
2019 Q4	$403K	Buy	12,409 +44	+0.4%	+$1.36K	﹤0.01%	2466
2019 Q3	$322K	Buy	12,365 +2,854	+30%	+$95.5K	﹤0.01%	2545
2019 Q2	$349K	Buy	+9,511	New	+$228K	﹤0.01%	2538

Other funds holding ODT

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

RhumbLine Advisers's ODT Position: Q2 2021 in Review

RhumbLine Advisers sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q2 2021, closing a stake of 17,002 shares — an estimated $58K sold.

RhumbLine Advisers first reported a position in ODT in Q2 2019 and held it in 8 quarters. The position peaked at $677K in Q2 2020. 69 funds tracked by Wall St. Rank hold ODT as of Q2 2021.

RhumbLine Advisers reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
RhumbLine Advisers sold 17,002 Odonate Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $58K.
RhumbLine Advisers first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
RhumbLine Advisers's Odonate Therapeutics, Inc. Common Stock position peaked at $677K in Q2 2020.
69 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.